1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Almirall SA

Almirall SA

10.32
EUR
-0.04
(-0.39%)
0.33EPS
34.14P/E
2.45BMarket Cap
Nov 09Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.2
4.58
3.85
4.27
3.56
4.2
9.44
4.36
4.42
4.24
4.09
4.54
5.1
6.51
Basic EPS, GAAP
-0.19
2.51
0.74
0.42
-1.69
0.43
0.58
0.4
-0.22
0.02
-0.18
0.05
0.21
0.33
Free Cash Flow per Basic Share
0.02
3.23
0.81
0.13
-0.35
-2.53
0.78
0.2
0.87
0.19
-0.3
- -
0.17
1.15
Dividend per Share
- -
- -
0.2
0.18
0.18
0.13
0.13
0.01
0.06
0.06
0.01
0.02
0.12
- -
Book Value per Share
5.14
7.75
8.46
8.79
6.55
6.85
7.34
7.32
7.15
7.27
7
6.98
6.93
7.03
Tangible Book Value per Share
-0.25
3.22
4.06
0.55
0.36
-1.41
-1
-0.13
0.3
0.57
0.94
1.1
1.29
1.55
Basic Weighted Avg Shares
179
179
179
179
179
180
181
185
187
204
219
217
217
217
Sales/Revenue/Turnover
752
819
689
764
639
757
1,711
807
827
863
895
986
1,108
1,411
Operating Margin (%)
2.16
69
18.09
12.69
2.53
14.74
59.43
13.59
13.46
7.97
4.61
4.74
6.02
29.09
Depreciation Expense
69
85
74
100
104
90
129
123
120
121
124
139
151
150
Net Income, GAAP
-34
448
132
75
-304
78
106
74
-41
4
-38
10
46
72
Effective Tax Rate (%)
- -
6.96
23.64
18.52
- -
- -
17.44
6.26
- -
86.2
- -
61.71
38.01
36.11
Profit Margin (%)
-4.49
54.75
19.13
9.87
-47.54
10.26
6.19
9.2
-4.94
0.5
-4.3
1.03
4.17
5.08
Working Capital
-63
746
846
367
167
170
160
15
218
278
368
388
363
423
LT Debt
254
332
333
331
263
532
492
243
378
387
386
391
325
338
Total Equity
888
1,340
1,463
1,520
1,134
1,192
1,280
1,303
1,286
1,319
1,463
1,488
1,487
1,530
Return on Invested Capital (%)
- -
32.65
7.27
4.91
- -
- -
6.99
4.78
- -
0.38
- -
0.72
2.39
13.67
Return on Capital (%)
- -
31.43
7.55
4.12
- -
- -
6.32
4.72
- -
0.31
- -
0.71
2.75
4.52
Return on Common Equity (%)
-3.72
40.26
9.41
5.06
-22.91
6.68
8.57
5.75
-3.16
0.33
-2.77
0.69
3.1
4.79

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
18
- -
18
LT Borrowings
290
285
307
LT Finance Leases
35
- -
32
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
215
215
218
Market Capitalization
2,777
2,606
2,455

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
714
699
747
Cash, Cash Equivalents & STI
339
311
355
Accounts Receivable, Net
145
163
166
Inventories
178
176
173
Total Current Liabilities
351
302
324
Payables & Accruals
- -
- -
- -
ST Debt
18
- -
18
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.67%
2.77%
-0.08%
Free Cash Flow
-583.13%
-1,158.33%
-5,695.03%
Net Income, GAAP
-170.02%
-207.15%
354.85%
Sales/Revenue/Turnover
11.92%
6.61%
12.41%
Total Cash Common Dividend
- -
220.38%
696.75%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
249
248
230
489
986
2025
286
274
260
548
1,108
2026
292
310
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.04
-0.04
-0.02
0.05
2025
0.1
0.02
0.06
0.09
0.21
2026
0.07
0.11
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carlos Gallardo Piqué
Full Time Employees
2,108
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ronda Del General Miter, 151 Barcelona CT Spain 08022
IPO Date
Apr 19, 2007
Website
almirall.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Almirall, S.A. Almirall, S.A. is a global biopharmaceutical company focused on medical dermatology that develops, manufactures and commercializes prescription treatments for skin diseases including psoriasis, atopic dermatitis, actinic keratosis, acne, rosacea, onychomycosis and androgenic alopecia; key products comprise Skilarence for psoriasis, Ilumetri, Wynzora (growing 32.4% year-over-year), Klisyri (growing 22.6% year-over-year), Ebglyss, Aczone, Tazorac, Seysara and Cordran Tape. Founded in 1944 and headquartered in Barcelona, Spain, the company operates through 14 affiliates across Europe and the US, with presence in over 100 countries, supported by R&D centers, chemical and pharmaceutical plants in Spain and Germany, and a workforce exceeding 2,000 employees representing 40 nationalities. Almirall, S.A. invests 12.6% of net sales in R&D, pursuing external innovation including expanded collaboration with Simcere on multispecific antibodies for immunodermatology and autoimmune kidney diseases, partnerships with Novo Nordisk and Eloxx Pharmaceuticals, initiation of a phase II study for anti-IL-1RAP mAb, plans for three additional proof-of-concept studies, a Microsoft collaboration for generative AI capabilities, and robust 2025 performance with 12.8% net sales growth in the first nine months driven by dermatology portfolio strength.